Comments
Loading...

Verona Pharma Analyst Ratings

VRNANASDAQ
Logo brought to you by Benzinga Data
Consensus Rating1
Buy
Highest Price Target1
$107.00
Lowest Price Target1
$31.00
Consensus Price Target1
$61.13

Verona Pharma Analyst Ratings and Price Targets | NASDAQ:VRNA | Benzinga

Verona Pharma PLC has a consensus price target of $61.13 based on the ratings of 8 analysts. The high is $107 issued by Wells Fargo on April 30, 2025. The low is $31 issued by BTIG on March 20, 2023. The 3 most-recent analyst ratings were released by Wells Fargo, HC Wainwright & Co., and Wells Fargo on April 30, 2025, April 30, 2025, and February 28, 2025, respectively. With an average price target of $95 between Wells Fargo, HC Wainwright & Co., and Wells Fargo, there's an implied 32.81% upside for Verona Pharma PLC from these most-recent analyst ratings.

Analyst Trends and Forecast
4
Jan
3
Feb
2
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Wells Fargo
HC Wainwright & Co.
Canaccord Genuity
Roth MKM
Truist Securities

1calculated from analyst ratings

Analyst Ratings for Verona Pharma

Buy NowGet Alert
04/30/2025Buy Now49.59%Wells Fargo
Tiago Fauth42%
$93 → $107MaintainsOverweightGet Alert
04/30/2025Buy Now18.83%HC Wainwright & Co.
Raghuram Selvaraju42%
$75 → $85MaintainsBuyGet Alert
02/28/2025Buy Now30.02%Wells Fargo
Tiago Fauth42%
$74 → $93MaintainsOverweightGet Alert
02/28/2025Buy Now4.85%HC Wainwright & Co.
Raghuram Selvaraju42%
$60 → $75MaintainsBuyGet Alert
02/12/2025Buy Now0.66%Canaccord Genuity
Edward Nash65%
$44 → $72MaintainsBuyGet Alert
01/21/2025Buy Now-16.12%HC Wainwright & Co.
Raghuram Selvaraju42%
$42 → $60ReiteratesBuy → BuyGet Alert
01/10/2025Buy Now-4.93%Roth MKM
Boobalan Pachaiyappan54%
→ $68Initiates → BuyGet Alert
01/08/2025Buy Now3.45%Wells Fargo
Tiago Fauth42%
$64 → $74MaintainsOverweightGet Alert
01/08/2025Buy Now-20.31%Truist Securities
Joon Lee75%
$44 → $57ReiteratesBuy → BuyGet Alert
11/05/2024Buy Now-10.53%Wells Fargo
Tiago Fauth42%
$50 → $64MaintainsOverweightGet Alert
11/05/2024Buy Now-41.28%HC Wainwright & Co.
Raghuram Selvaraju42%
$36 → $42MaintainsBuyGet Alert
11/05/2024Buy Now-38.49%Canaccord Genuity
Edward Nash65%
$37 → $44MaintainsBuyGet Alert
10/09/2024Buy Now-38.49%Truist Securities
Joon Lee75%
$38 → $44MaintainsBuyGet Alert
10/03/2024Buy Now-30.1%Wells Fargo
Tiago Fauth42%
→ $50Initiates → OverweightGet Alert
10/01/2024Buy Now-49.67%HC Wainwright & Co.
Raghuram Selvaraju42%
$36 → $36ReiteratesBuy → BuyGet Alert
09/17/2024Buy Now-49.67%HC Wainwright & Co.
Raghuram Selvaraju42%
$36 → $36ReiteratesBuy → BuyGet Alert
09/11/2024Buy Now-49.67%HC Wainwright & Co.
Raghuram Selvaraju42%
$36 → $36ReiteratesBuy → BuyGet Alert
07/22/2024Buy Now-48.27%Canaccord Genuity
Edward Nash65%
$35 → $37MaintainsBuyGet Alert
07/01/2024Buy Now-49.67%HC Wainwright & Co.
Raghuram Selvaraju42%
$36 → $36ReiteratesBuy → BuyGet Alert
06/28/2024Buy Now-46.88%Truist Securities
Joon Lee75%
$32 → $38MaintainsBuyGet Alert
06/27/2024Buy Now-51.07%Canaccord Genuity
Edward Nash65%
$35 → $35MaintainsBuyGet Alert
06/27/2024Buy Now-49.67%HC Wainwright & Co.
Raghuram Selvaraju42%
$32 → $36MaintainsBuyGet Alert
05/15/2024Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
$32 → $32ReiteratesBuy → BuyGet Alert
05/13/2024Buy Now-58.06%HC Wainwright & Co.
Raghuram Selvaraju42%
$33 → $30MaintainsBuyGet Alert
04/16/2024Buy Now-49.67%Piper Sandler
Yasmeen Rahimi54%
$31 → $36MaintainsOverweightGet Alert
03/04/2024Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
$32 → $32ReiteratesBuy → BuyGet Alert
03/01/2024Buy Now-53.87%Wedbush
Liana Moussatos77%
→ $33ReiteratesOutperform → OutperformGet Alert
01/22/2024Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
$32 → $32ReiteratesBuy → BuyGet Alert
12/29/2023Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
$32 → $32ReiteratesBuy → BuyGet Alert
09/11/2023Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
→ $32ReiteratesBuy → BuyGet Alert
09/01/2023Buy Now-51.07%Canaccord Genuity
Edward Nash65%
→ $35ReiteratesBuy → BuyGet Alert
08/04/2023Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
→ $32ReiteratesBuy → BuyGet Alert
06/28/2023Buy Now-58.06%Wedbush
Liana Moussatos77%
→ $30ReiteratesOutperform → OutperformGet Alert
06/27/2023Buy Now-55.26%Truist Securities
Joon Lee75%
→ $32ReiteratesBuy → BuyGet Alert
06/27/2023Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
→ $32ReiteratesBuy → BuyGet Alert
06/07/2023Buy Now-55.26%Truist Securities
Joon Lee75%
$28 → $32MaintainsBuyGet Alert
06/02/2023Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
→ $32ReiteratesBuy → BuyGet Alert
05/10/2023Buy Now-53.87%Canaccord Genuity
Edward Nash65%
$31 → $33MaintainsBelow AverageGet Alert
05/10/2023Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
→ $32Reiterates → BuyGet Alert
04/10/2023Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
→ $32Reiterates → BuyGet Alert
03/20/2023Buy Now-56.66%BTIG
Thomas Shrader39%
$26 → $31MaintainsBuyGet Alert
03/13/2023Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
→ $32Reiterates → BuyGet Alert
12/21/2022Buy Now-55.26%HC Wainwright & Co.
Raghuram Selvaraju42%
$30 → $32MaintainsBuyGet Alert
12/20/2022Buy Now-60.86%Truist Securities
Joon Lee75%
$20 → $28MaintainsBuyGet Alert
12/20/2022Buy Now-63.65%BTIG
Thomas Shrader39%
$17 → $26MaintainsBuyGet Alert
08/29/2022Buy Now-58.06%HC Wainwright & Co.
Raghuram Selvaraju42%
$25 → $30MaintainsBuyGet Alert
08/26/2022Buy Now-56.66%Piper Sandler
Yasmeen Rahimi54%
→ $31Initiates → OverweightGet Alert
06/17/2022Buy Now-74.84%Wedbush
Liana Moussatos77%
$25 → $18MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Verona Pharma (VRNA) stock?

A

The latest price target for Verona Pharma (NASDAQ:VRNA) was reported by Wells Fargo on April 30, 2025. The analyst firm set a price target for $107.00 expecting VRNA to rise to within 12 months (a possible 49.59% upside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verona Pharma (VRNA)?

A

The latest analyst rating for Verona Pharma (NASDAQ:VRNA) was provided by Wells Fargo, and Verona Pharma maintained their overweight rating.

Q

When was the last upgrade for Verona Pharma (VRNA)?

A

There is no last upgrade for Verona Pharma

Q

When was the last downgrade for Verona Pharma (VRNA)?

A

There is no last downgrade for Verona Pharma.

Q

When is the next analyst rating going to be posted or updated for Verona Pharma (VRNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verona Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verona Pharma was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.

Q

Is the Analyst Rating Verona Pharma (VRNA) correct?

A

While ratings are subjective and will change, the latest Verona Pharma (VRNA) rating was a maintained with a price target of $93.00 to $107.00. The current price Verona Pharma (VRNA) is trading at is $71.53, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch